Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

被引：0

作者：

le Coutre, Philipp D. ^{[1
]}

Giles, Francis ^{[2
]}

Hochhaus, Andreas ^{[3
]}

Apperley, Jane F. ^{[4
]}

Ossenkoppele, Gert ^{[5
]}

Haque, Ariful ^{[6
]}

Gallagher, Neil J. ^{[7
]}

Baccarani, Michele ^{[8
]}

Cortes, Jorge ^{[9
]}

Kantarjian, Hagop M. ^{[9
]}

机构：

[1] Humboldt Univ, Dept Hematol & Oncol, Charite, Berlin, Germany

[2] Univ Texas Hlth Sci Ctr San Antonio, CTRC, Inst Drug Dev, San Antonio, TX 78229 USA

[3] Univ Heidelberg, Fak Med, D-6800 Mannheim, Germany

[4] Hammersmith Hosp, Dept Hematol, London, England

[5] Vrije Univ Amsterdam, Med Ctr, Dept Hematol Br 2, Amsterdam, Netherlands

[6] Novartis Pharmaceut, Florham Pk, NJ USA

[7] Novartis Pharma AG, Oncol, Basel, Switzerland

[8] Inst Hematol & Med OncologySeragnoli, Bologna, Italy

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1108 / 1109

页数：2